Kristin Karlsson

Scientific and regulatory evaluation of mechanistic <i>in silico</i> drug and disease models in drug development: Building model credibility

Flora T. Musuamba, Ine Skottheim Rusten, R Lesage et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 133 citations · Full text

Engineering, Risk Model Validation, Verification +24

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014)

FT. Musuamba, Efthymios Manolis, Nicholas H. G. Holford et al. · CPT Pharmacometrics & Systems Pharmacology · 2017 · 67 citations · Full text

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis

Maria Andersson, Ingemar F. Petersson, Kristin Karlsson et al. · Annals of the Rheumatic Diseases · 2006 · 66 citations · Full text

Commentary on the <scp>EMA R</scp>eflection <scp>P</scp>aper on the use of extrapolation in the development of medicines for paediatrics

Cécile Ollivier, Andrew Thomson, Efthymios Manolis et al. · British Journal of Clinical Pharmacology · 2019 · 42 citations · Full text

Evidence-based Medicine, Education, New Series +16

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Elke H. J. Krekels, Ronald Niebecker, Mats O. Karlsson et al. · Clinical Pharmacokinetics · 2016 · 32 citations

Cardiovascular Disease, Non-valvular Atrial Fibrillation, Pharmacology +9